Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct thrombin inhibitors.
Chen MS, Lincoff AM. Chen MS, et al. Among authors: lincoff am. Curr Cardiol Rep. 2005 Jul;7(4):255-9. doi: 10.1007/s11886-005-0046-y. Curr Cardiol Rep. 2005. PMID: 15987622 Review.
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ. Lincoff AM, et al. Am J Cardiol. 1997 Feb 1;79(3):286-91. doi: 10.1016/s0002-9149(96)00749-7. Am J Cardiol. 1997. PMID: 9036746 Clinical Trial.
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Lincoff AM, et al. J Am Coll Cardiol. 1997 Jul;30(1):149-56. doi: 10.1016/s0735-1097(97)00110-1. J Am Coll Cardiol. 1997. PMID: 9207636 Free article. Clinical Trial.
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ. Ghaffari S, et al. Among authors: lincoff am. Am J Cardiol. 1998 Jul 1;82(1):7-12. doi: 10.1016/s0002-9149(98)00238-0. Am J Cardiol. 1998. PMID: 9671000 Clinical Trial.
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ. Ellis SG, et al. Among authors: lincoff am. J Am Coll Cardiol. 1998 Nov 15;32(6):1619-23. doi: 10.1016/s0735-1097(98)00403-3. J Am Coll Cardiol. 1998. PMID: 9822087 Free article. Clinical Trial.
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Lincoff AM, et al. Circulation. 1999 Apr 20;99(15):1951-8. doi: 10.1161/01.cir.99.15.1951. Circulation. 1999. PMID: 10208997 Clinical Trial.
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ. Lincoff AM, et al. N Engl J Med. 1999 Jul 29;341(5):319-27. doi: 10.1056/NEJM199907293410503. N Engl J Med. 1999. PMID: 10423466 Free article. Clinical Trial.
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Marso SP, et al. Among authors: lincoff am. Circulation. 1999 Dec 21-28;100(25):2477-84. doi: 10.1161/01.cir.100.25.2477. Circulation. 1999. PMID: 10604884 Clinical Trial.
427 results